SARS-CoV-2, Influenza A+B, RSV Antigen combined test sheet from nasopharyngeal swab, 20 pieces

The SARS-CoV-2/Influenza A+B/RSV Antigen Combined Rapid Test (Nasopharyngeal Swab) is a chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Influenza A Influenza B and Respiratory Syncytial Virus (RSV) antigens present in the human nasopharynx, in cases where a combined clinical presentation and other laboratory findings suggest the presence of SARS-CoV-2/Influenza/RSV infection. The results refer to the overall detection of SARS-CoV-2 nucleocapsid protein, Influenza A+B and RSV antigens. The antigen is usually detectable in the upper respiratory tract during the acute phase of infection. A positive result confirms the presence of viral antigens, but a clinical picture and the patient's medical history and other diagnostic information are required to confirm infection. Positive results do not exclude infection with other bacterial or other viruses. Furthermore, it is not certain that the pathogen detected is the cause of the symptoms. A negative result does not exclude SARS-CoV-2/Influenza A+B/RSV infection and should not be used as the sole basis for treatment decisions. Molecular techniques should be used to confirm negative results when necessary for patient management. In the case of a negative result, the patient's possible exposure to SARS-COV-2/Influenza A+B/RSV infection, the medical history and clinical signs consistent with SARS-COV-2/Influenza A+B/RSV should also be taken into account.